Free tool
FAERS Monitor: Wayrilz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219685 or its brand name (Wayrilz, Rilzabrutinib). Reports on generic versions are filed under their own applications.
Reports
564
Serious
113
20% of reports
Hospitalization
83
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- platelet count decreased143
- diarrhoea142
- nausea105
- drug ineffective92
- headache52
- fatigue50
- product use in unapproved indication47
- abdominal discomfort39
- vomiting29
- dizziness23
- arthralgia21
- asthenia21
- platelet count abnormal20
- abdominal pain upper19
- dyspepsia16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 110 |
| 2026 | 452 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| platelet count abnormalSignal | 20 | 123.8 | 80.4 | 2,308 |
| platelet count decreasedSignal | 143 | 50.1 | 43.5 | 6,858 |
| abdominal discomfortSignal | 39 | 8.7 | 6.4 | 259 |
| diarrhoeaSignal | 142 | 8.2 | 7.1 | 919 |
| product use in unapproved indicationSignal | 47 | 7.1 | 5.4 | 242 |
| dyspepsiaSignal | 16 | 6.1 | 3.7 | 63 |
| nauseaSignal | 105 | 4.9 | 4.2 | 340 |
| abdominal pain upperSignal | 19 | 3.4 | 2.2 | 31 |
| headacheSignal | 52 | 3.1 | 2.4 | 74 |
| drug ineffectiveSignal | 92 | 2.6 | 2.2 | 95 |
| fatigueSignal | 50 | 2.4 | 1.8 | 41 |
| vomitingSignal | 29 | 2.3 | 1.6 | 20 |
| astheniaSignal | 21 | 2.1 | 1.4 | 11 |
| arthralgia | 21 | 1.9 | 1.2 | 8 |
| dizziness | 23 | 1.7 | 1.2 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.